Congenital anomaly of the mitral subvalvular apparatus

Summary

Congenital anomaly of the mitral subvalvular apparatus (MONDO:0015109) is a disease. A subtype of mitral valve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	congenital anomaly of the mitral subvalvular apparatus
Mondo ID	MONDO:0015109
Orphanet	101932
ICD-11	498751490
UMLS	C3164517
MedGen	756923
GARD	0019784
Is cancer (heuristic)	no

Disease family

This is a subtype of mitral valve disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart valve disorder › mitral valve disorder › congenital anomaly of the mitral subvalvular apparatus

Related subtypes (6): mitral valve prolapse, mitral valve stenosis, mitral atresia disorder, inherited mitral valve disease, rheumatic disease of mitral valve, mitral valve insufficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.